The proof that PMP22 was the gene involved in CMT was provided when two rare non-duplicated CMT Some clues to the complexities of CMT may be provided by experience in retinitis pigmentosa. For many years it has been known that CMT, like retinitis pigmentosa, is one of a few diseases showing dominant, X linked, and recessive modes of inheritance.'8 This suggests involvement of a family of genes with similar functions. This has proved to be true in CMT type I where all mutations found so far involve Schwann cell membrane and myelin proteins; CMT may therefore be similar to retinitis pigmentosa at a molecular level. Two or more proteins may interact between adjacent membranes (in CMT between myelin lamellae and in retinitis Nicholson pigmentosa between photoreceptor discs) explaining how mutations in different proteins can produce a similar syndrome if they are part of the same protein complex.
In some families with retinitis pigmentosa two interacting proteins must be mutated to produce disease. This is a new class of mutations, which on their own may be innocuous but when combined, produce disease. In retinitis pigmentosa, such families have a pattern of inheritance that looks incompletely dominant and have been described as showing digenic inheritance.19 Such mutations may cause some of the rarer types of CMT. Interaction with a second protein would also account for PMP22 gene dosage sensitivity; alternatively PMP22 protein may form an ion channel. Mutations altering channel function or giving increased numbers of channels in patients with CMT duplications could also explain gene dosage sensitivity.
Most families (60%-80%) with severe slowing of motor nerve conduction (HMSN I) have the chromosome 17 Mutations in the proteolipid protein (PLP) gene produce the Pelizaeus-Merzbacher syndrome. This syndrome can rarely be caused by PLP duplications.33 The PLP protein has a similar structure to PMP22 and is thought to be its CNS equivalent. This suggests that both myelin genes may be dosage sensitive and a rule may be emerging; that the dominant, mild, CMT type I syndromes are myelin gene dosage disorders where the CMT phenotype is caused by overdosage and the HNPP phenotype results from underdosage. The severe syndromes (cases with severe wasting or requiring wheelchairs in young adulthood) may appear sporadic or be recessive and may be due to point mutations in myelin genes with a different pathogenesis.
One can speculate that PO may also have both gain of function and loss of function mutations. If the effect of dosage of PO is the same as for PMP22, one could predict that mutations leading to loss of PO function or decreased gene expression would produce tomacula. This would explain a report of a CMT1B family with no clinical evidence of pressure sensitivity, which surprisingly had profuse tomacula on sural nerve biopsy.34 As in CMT1A, the other CMT1B PO point mutations may be gain of function mutations producing the CMT type I phenotype. So far there is no direct evidence for overexpression but a patient with the Dejerine-Sottas phenotype due to a PO point mutation did not have reduced expression or a truncated product. 35 One PO frame shift (null) mutation was reported as a clinical CMT1B case but it is not known if tomacula were present as a sural nerve biopsy result was not reported.36 Clinical diagnosis can be difficult as there is overlap between the CMT and HNPP syndromes. Some families with tomaculous neuropathy on biopsy have been reported with a "CMT" phenotype with pes cavus, slow motor conductions, and no evidence of pressure sensitivity.37
If the dosage scheme is true it is hard to see how recessive disorders of the PMP22 and PO myelin genes can produce a CMT (overdose) syndrome. A recessive PMP22 point mutation (thought to be recessive as subjects with the mutation on its own were normal) combined with a deletion is associated with a severe CMT phenotype.30 A second apparent exception is a frame shift PMP22 mutation (which should reduce PMP22 expression) associated with a CMT phenotype. 
